Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;10(3):219–229. doi: 10.1111/j.1527-3458.2004.tb00023.x

Preclinical and Clinical Pharmacology of Cyamemazine: Anxiolytic Effects and Prevention of Alcohol and Benzodiazepine Withdrawal Syndrome

Michel Bourin 1,2,✉, Eric Dailly 1, Martine Hascöet 1
PMCID: PMC6741725  PMID: 15492772

ABSTRACT

Several studies have suggested that the antipsychotic compound, cyamemazine, possesses anxiolytic properties in humans. The original pharmacological profile of cyamemazine (D2, 5‐HT2A, 5‐HT2C, and 5‐HT3 receptor antagonist), which was established by binding, microdialysis and behavioral studies, is consistent with these observations. In the light/dark exploration test, cyamemazine demonstrated anxiolytic‐like activity by acute, but not chronic administration. By chronic administration, however, cyamemazine increased the time spent in the open arms of the elevated plus maze (EPM) test demonstrating anxiolytic‐like activity. The discrepancy between the results obtained in these tests by acute and chronic administration, could be due to a combination of dopamine D2 receptor antagonism with antagonism of the 5‐HT2C and 5‐HT3 receptors. The action of cyamemazine on both the dopaminergic system and 5‐HT3 receptors could also explain the activity of cyamemazine in the management of alcohol withdrawal demonstrated in preclinical studies. This potential indication for cyamemazine and its activity in benzodiazepine withdrawal syndrome have recently been investigated in clinical trials and the results of these studies are presented in this review.

Keywords: 5‐HT3‐receptors, HT2C receptors, Antipsychotics, Anxiety, Cyamemazine

Full Text

The Full Text of this article is available as a PDF (101.1 KB).

REFERENCES

  • 1. Alvarez‐Guerra M, D'Alché‐Birée F, Wolf WA, Vargas F, Dib M, Garay RP. 5‐HT3 and 5‐HT2C antagonist properties of cyamemazine: Significance for its clinical anxiolytic activity. Psychopharmacology 2000;147:412–417. [DOI] [PubMed] [Google Scholar]
  • 2. Alvarez‐Guerra M, Hameg A, Bayle F, Dib M, Garay RP. 5‐HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle. Eur J Pharmacol 2002;454:235–239. [DOI] [PubMed] [Google Scholar]
  • 3. Archambault JC, Théodore F, Minne P. Utilisation du Tercian en monothérapie dans l'alcoolisme chronique (àpropos de 78 observations). Actualités Psychiatriques 1986;10:118–121. [Google Scholar]
  • 4. Amt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63–101. [DOI] [PubMed] [Google Scholar]
  • 5. Balldin J, Berggren U, Lindstedt G, Sunder A. Further neuroendocrine evidence for reduced D2 dopamine receptor function in alcoholism. Drug Alcohol Depend 1993;32:159–162. [DOI] [PubMed] [Google Scholar]
  • 6. Barrett E, Vanover KE. 5‐HT receptors as targets for the development of novel anxiolytic drugs: Models, mechanisms and future directions. Psychopharmacology 1993;112:1–12. [DOI] [PubMed] [Google Scholar]
  • 7. Belzung C, Le Pape G, Comparison of different behavioural test situations used in psychopharmacology for measurement of anxiety. Physiol Behav 1994;56:63–68. [DOI] [PubMed] [Google Scholar]
  • 8. Bleichner G, Squara P, Parent A. Hypertonia and malignant hyperthermia due to morphine and neuroleptic. Lancet 1981;1:386–387. [DOI] [PubMed] [Google Scholar]
  • 9. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996;16:38–44. [DOI] [PubMed] [Google Scholar]
  • 10. Bourin M, Dailly E, Hameg A, Dib M, Garay R P, Hascoët M. Antipsychotic‐like activity of cyamemazine in mouse behavioral models. Fund Clin Pharmacol (submitted).
  • 11. Bourin M, Nic Dhonnchadha BA, Colombel MC, Dib M, Hascoet M. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res 2001;124:87–95. [DOI] [PubMed] [Google Scholar]
  • 12. Colonna L. Effets paradoxaux des neuroleptiques. Encephale 1976;2:197–200. [PubMed] [Google Scholar]
  • 13. Corbett R, Hartman H, Keeman LL et al. Effects of atypical antipsychotic agents on social behaviour in rodents. Pharmacol Biochem Behav 1993;45:9–17. [DOI] [PubMed] [Google Scholar]
  • 14. Costall B, Naylor RJ. Anxiolytic potential of 5‐HT3 receptor antagonists. Pharmacol Toxicol 1992;70:157–162. [DOI] [PubMed] [Google Scholar]
  • 15. Costall B, Naylor RJ. Behavioural interactions between 5‐hydroxytryptophan, neuroleptic agents and 5‐HT receptor antagonists in modifying rodent responding to aversive situations. Br J Pharmacol 1995;116:2989–2999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Daskalopoulos NT, Cottereau MJ, Picchi E. Approche de la résistance aux traitements par associations de neuroleptiques. Ann Med Psychol 1977;2:333–351. [PubMed] [Google Scholar]
  • 17. Deakin JFW. The role of serotonin in panic, anxiety and depression. Int Clin Psychopharmacol 1998;13(Suppl 4):S1–S5. [DOI] [PubMed] [Google Scholar]
  • 18. Dequiedt P, Lelievre G, Dracon M, Lemaitre V, Tacquet A. Les insuffisances rénales aigües toxiques iatrogènes. Apropos de 95 observations. LARC Med 1981;1:11–12. [PubMed] [Google Scholar]
  • 19. Destee A, Montagne B, Rousseaux M, Petit H, Warot P. Incidents et accidents des neuroleptiques (110 hospitalisations en neurologie). Lille Med 1980;25:291–295. [PubMed] [Google Scholar]
  • 20. Dubroca JM. L'anxiolyse: intérêt de la cyamémazine. Neuro-Psy 1989;4:4–7. [Google Scholar]
  • 21. Fadda F, Garau B, Marchei F, Colombo G, Gessa GL. MDL72222 selective 5‐HT3 receptor antagonist suppresses voluntary ethanol consumption in alcohol‐preferring rats. Alcohol Alcohol 1991;26:107–110. [DOI] [PubMed] [Google Scholar]
  • 22. Faurel JP, Delas N, Saigot T, Sarrazin A. Entérocolites nécrosantes après prise prolongée de neuroleptiques. Apropos de 4 observations. Med Chir Dig 1981;10:621–622. 7329129 [Google Scholar]
  • 23. Favre JD, Allain H, Aubin HJ, et al. Alcohol withdrawal syndrome: Clinical efficacy of cyamemazine in comparison with diazepam. J Clin Psychopharmacol (Submitted).
  • 24. Garay RP, D'Alché‐Birée F. Cyamémazine (Tercian®): profil neuroleptique ou anxiolytique L'Inf Psychiatr 1995;10:969–970. [Google Scholar]
  • 25. Gauthier‐Lafaye P, Mergy P, Nuret G, Pomes JC. Etude sur les résultats cliniques obtenus par le Tercian. Psychol Méd 1976;8:1113–1120. [Google Scholar]
  • 26. Giroud JP, Mathé G, Meyniel G. Neuroleptiques In: Pharmacologie clinique — bases de la thérapeutique. Paris : Expansion scientifique, 1979;1651–1672. [Google Scholar]
  • 27. Griebel G. 5‐hydroxytryptamine‐interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmacol Ther 1995;65:319–395. [DOI] [PubMed] [Google Scholar]
  • 28. Griebel G, Perrault G, Sanger DJ. A comparative study of the effects of selective and non‐selective 5‐HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 1997;36:793–802. [DOI] [PubMed] [Google Scholar]
  • 29. Griebel G. Variability in the effects of 5‐HT‐related compounds in experimental models of anxiety: Evidence for multiple mechanisms of 5‐HT in anxiety or never ending story Pol J Pharmacol 1996;48:129–136. [PubMed] [Google Scholar]
  • 30. Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M. Affinity of cyamemazine, an anxiolytic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol 2003;65:435–440. [DOI] [PubMed] [Google Scholar]
  • 31. Handley SL, McBlane JW. 5‐HT drugs in animal models of anxiety. Psychopharmacology 1993;112:13–20. [DOI] [PubMed] [Google Scholar]
  • 32. Handley SL, McBlane JW, Critchley MA, Njung'e K. Multiple serotonin mechanisms in animal models of anxiety: Environmental, emotional and cognitive factors. Behav Brain Res 1993;58:203–210. [DOI] [PubMed] [Google Scholar]
  • 33. Handley SL, McBlane JW. Serotonin mechanisms in animal models of anxiety. Braz J Med Biol Res 1993;26:1–13. [PubMed] [Google Scholar]
  • 34. Hascoët M, Bourin M, Nic Dhonnchadha BÁ. The mouse‐light‐dark paradigm: a review. Prog Neuro-Psychopharmacol Biol Psychiatry 2001;25:141–166. [DOI] [PubMed] [Google Scholar]
  • 35. Hilbert A, Maier W, Wetzel H, Benkart O. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: A functional approach. Pharmacopsychiatry 1992;25:213–217. [DOI] [PubMed] [Google Scholar]
  • 36. Hillemand B, Leroy J, Joly JP, Le Grix A. Etat fébrile avec insuffisance rénale aigüe ayant nécessité une épuration extra‐rénale, guérison. Rôle vraisemblable du butyrophénone. Sem Hop 1976;52:953–957. [PubMed] [Google Scholar]
  • 37. Jenck F. The role of 5‐HT2C receptors in affective disorders. Exp Opin Invest Drugs 1998;7:1587–1599. [DOI] [PubMed] [Google Scholar]
  • 38. Kaplan M. Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry 2000;61:388–389. [DOI] [PubMed] [Google Scholar]
  • 39. Kleinknecht D, Parent A, Blot P, Bochereau G, Lallement PY, Pourriat JL. Rhabdomyolyse avec insuffisance rénale aigüe et syndrome malin des neuroleptiques. Ann Med Intern 1982;133:549–552. [PubMed] [Google Scholar]
  • 40. Le Bellec M, Bismuth C, Lagier G, Dally S. Syndrome de sevrage sévère après arrêt des benzodiazépines — six cas cliniques. Therapie 1980;35:113–118. [PubMed] [Google Scholar]
  • 41. Lemoine P, Dib M. Use of cyamemazine in facilitating benzodiazepine withdrawal: A bromazepam‐controlled study. Addiction (Submitted).
  • 42. Linseman MA. Effects of dopaminergic agents on alcohol consumption by rats in a limited access paradigm. Psychopharmacology 1990;100:195–200. [DOI] [PubMed] [Google Scholar]
  • 43. Lucas G, De Deurwaerdere P, Caccia S, Spampinato U. The effect of serotoninergic agents on haloperidol‐induced striatal dopamine release in vivo: Opposite role of 5‐HT2A and 5‐HT2C receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 2000;39:1053–1063. [DOI] [PubMed] [Google Scholar]
  • 44. Meert TF. Effects of various serotoninergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. Alcohol Alcohol 1993;28:157–170. [PubMed] [Google Scholar]
  • 45. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21(Suppl 2):S106–S115. [DOI] [PubMed] [Google Scholar]
  • 46. Naassila M, Legrand E, D'Alche‐Birée F, Daoust M. Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in rats. Psychopharmacology 1998;140:421–428. [DOI] [PubMed] [Google Scholar]
  • 47. Nowakowska E, Chodera A, Kus K, Rybakowski J. Some behavioural effects of risperidone in rats: Comparison with haloperidol. Eur Neuropsychopharmacol 1999;9:421–426. [DOI] [PubMed] [Google Scholar]
  • 48. Olivier B, Van Wijngaarden I, Soudijn W. 5‐HT3 receptor antagonists and anxiety: A preclinical and clinical review. Eur Neuropsychopharmacol 2000;10:77–95. [DOI] [PubMed] [Google Scholar]
  • 49. Paleologue A, Varouchakis H. Etude de l'activité d'un nouveau neuroleptique. Inf Psychiatr 1976;52:249–256. [Google Scholar]
  • 50. Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M. Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine. Naunyn Schmiedeberg's Arch Pharmacol 2003;367:134–139. [DOI] [PubMed] [Google Scholar]
  • 51. Radat F. Cyamémazine: traitement symptomatique des dimensions anxieuses, impulses et agressives. L'Inf Psychiatr 1995;10:967–968. [Google Scholar]
  • 52. Rager P, Cosculluela D, Deviers D. Hépatite médicamenteuse — Rôle possible de la cyamémazine. Presse Med 1983;12:1941. [PubMed] [Google Scholar]
  • 53. Richelson E. Receptor pharmacology of neuroleptics: Relation to clinical effects. J Clin Psychiatry 1999;60:5–14. [PubMed] [Google Scholar]
  • 54. Roca J, Artaiz I, Delrio J. 5‐HT3 receptor antagonists in development as anxiolytics. Exp Opin Invest Drugs 1995;4:333–342. [Google Scholar]
  • 55. Rodgers RJ, Nikulina EM, Cole JC. Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus maze. Pharmacol Biochem Behav 1994;49:985–995. [DOI] [PubMed] [Google Scholar]
  • 56. Ropert R, Abitbol JP. Emploi de la cyamemazine dans le traitement de certains états anxio‐dépressifs. Rev Française Psych 1986;4:34–38. [Google Scholar]
  • 57. Sakamoto H, Matsumoto K, Yukihiro O, Nakumura M. Anxiolytic‐like effects of perospirone, a novel serotonin‐2 and dopamine‐2 antagonist (SDA)‐type antipsychotic agent. Pharmacol Biochem Behav 1998;60:873–878. [DOI] [PubMed] [Google Scholar]
  • 58. Sánchez C, Arnt J. In vivo assessment of 5‐HT2A and 5‐HT2C antagonistic properties of newer antipsychotics. Behav Pharmacol 2000;11:291–298. [DOI] [PubMed] [Google Scholar]
  • 59. Soloff PH. Neuroleptic treatment in the borderline patient: Advantages and techniques. J Clin Psychiatry 1987;48:26–31. [PubMed] [Google Scholar]
  • 60. Sullivan JT, Sykora K, Scheiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol intake (CIWA‐Ar). Br J Addict 1989;84:1353–1357. [DOI] [PubMed] [Google Scholar]
  • 61. Wiley JL, Compton AD, Porter JH. Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 1993;45:263–267. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES